fampridine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4163 504-24-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fampyra
  • dalfampridine
  • ampyra
  • pyridin-4-amine
  • 4-aminopyridine
  • fampridine
One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.
  • Molecular weight: 94.12
  • Formula: C5H6N2
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: 0.46
  • ROTB: 0

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90.30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.04 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 2010 FDA ACORDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 1628.26 14.25 739 34330 41386 46609607
Urinary tract infection 1302.61 14.25 1172 33897 219094 46431899
Gait disturbance 1264.72 14.25 968 34101 144295 46506698
Laboratory test abnormal 997.36 14.25 437 34632 22410 46628583
Multiple sclerosis 859.88 14.25 404 34665 24387 46626606
Balance disorder 697.22 14.25 491 34578 64030 46586963
Urine analysis abnormal 596.84 14.25 191 34878 3999 46646994
Fall 505.87 14.25 892 34177 328205 46322788
Therapy cessation 384.53 14.25 243 34826 26386 46624607
Muscular weakness 330.19 14.25 375 34694 91469 46559524
Seizure 231.17 14.25 366 34703 122688 46528305
Insomnia 209.37 14.25 413 34656 164511 46486482
Escherichia urinary tract infection 205.74 14.25 116 34953 10207 46640786
Muscle spasticity 199.89 14.25 118 34951 11322 46639671
Gait inability 167.51 14.25 167 34902 35036 46615957
Rheumatoid arthritis 165.60 14.25 3 35066 240212 46410781
Peroneal nerve palsy 153.81 14.25 71 34998 4097 46646896
B-lymphocyte count decreased 153.61 14.25 46 35023 764 46650229
Inappropriate schedule of product administration 145.52 14.25 210 34859 64803 46586190
Dizziness 139.21 14.25 564 34505 339850 46311143
Drug ineffective 138.31 14.25 924 34145 676914 45974079
Central nervous system lesion 136.83 14.25 87 34982 9528 46641465
Toxicity to various agents 133.74 14.25 6 35063 211760 46439233
Secondary progressive multiple sclerosis 131.17 14.25 45 35024 1175 46649818
Lymphocyte count decreased 128.42 14.25 125 34944 25464 46625529
Therapeutic response unexpected 128.29 14.25 101 34968 15515 46635478
Hypoaesthesia 126.39 14.25 277 34792 118592 46532401
Culture urine positive 125.87 14.25 58 35011 3333 46647660
Memory impairment 120.88 14.25 212 34857 77125 46573868
Urine leukocyte esterase positive 115.34 14.25 50 35019 2485 46648508
Dyspnoea 106.73 14.25 139 34930 515409 46135584
Paraesthesia 106.43 14.25 257 34812 117180 46533813
Flushing 106.02 14.25 181 34888 64433 46586560
Mobility decreased 101.08 14.25 171 34898 60423 46590570
Micturition urgency 97.20 14.25 65 35004 7752 46643241
Anaemia 96.19 14.25 36 35033 255743 46395250
Asthenia 93.63 14.25 471 34598 310604 46340389
Pollakiuria 90.27 14.25 101 34968 24160 46626833
Walking aid user 85.11 14.25 50 35019 4750 46646243
Completed suicide 80.82 14.25 8 35061 145912 46505081
JC polyomavirus test positive 78.95 14.25 29 35040 928 46650065
T-lymphocyte count increased 78.04 14.25 18 35051 98 46650895
Urinary incontinence 77.10 14.25 101 34968 28429 46622564
Off label use 76.84 14.25 104 34965 379737 46271256
Lymphopenia 75.39 14.25 74 34995 15219 46635774
Head injury 74.12 14.25 92 34977 24544 46626449
Acute kidney injury 73.54 14.25 43 35026 235812 46415181
CD4 lymphocytes increased 72.18 14.25 18 35051 143 46650850
T-lymphocyte count decreased 71.67 14.25 20 35049 255 46650738
Progressive multiple sclerosis 69.06 14.25 25 35044 767 46650226
Trigeminal neuralgia 68.94 14.25 37 35032 2952 46648041
Neurogenic bladder 64.27 14.25 35 35034 2875 46648118
Product substitution issue 61.87 14.25 66 35003 14965 46636028
Motor dysfunction 61.75 14.25 48 35021 7234 46643759
Dysstasia 61.39 14.25 71 34998 17597 46633396
Depression 59.31 14.25 269 34800 169835 46481158
Influenza like illness 58.66 14.25 132 34937 57438 46593555
Red blood cells urine positive 56.59 14.25 31 35038 2576 46648417
Neutropenia 55.74 14.25 19 35050 143185 46507808
Hypotension 54.07 14.25 57 35012 232532 46418461
White blood cells urine positive 53.16 14.25 35 35034 4065 46646928
Exposure during pregnancy 52.55 14.25 9 35060 108203 46542790
Pneumonia 52.03 14.25 130 34939 376190 46274803
CD4 lymphocytes decreased 51.94 14.25 25 35044 1585 46649408
CD8 lymphocytes decreased 50.72 14.25 14 35055 171 46650822
Febrile neutropenia 50.31 14.25 6 35063 94621 46556372
Dysgraphia 49.28 14.25 29 35040 2763 46648230
Drug hypersensitivity 48.97 14.25 67 35002 243758 46407235
Adverse drug reaction 48.91 14.25 105 34964 44257 46606736
Diarrhoea 48.03 14.25 237 34832 559365 46091628
Temperature intolerance 47.51 14.25 42 35027 7565 46643428
Gait spastic 47.00 14.25 14 35055 228 46650765
Epilepsy 46.37 14.25 72 34997 23666 46627327
Product dose omission issue 46.26 14.25 249 34820 168271 46482722
Loss of control of legs 46.19 14.25 22 35047 1362 46649631
Dysuria 44.34 14.25 77 34992 27756 46623237
Primary progressive multiple sclerosis 44.26 14.25 11 35058 86 46650907
Lymphocyte count abnormal 43.92 14.25 17 35052 630 46650363
Progressive multifocal leukoencephalopathy 43.51 14.25 48 35021 11298 46639695
Gastrointestinal haemorrhage 43.46 14.25 4 35065 77369 46573624
Haemoglobin urine present 43.44 14.25 17 35052 649 46650344
Ataxia 41.86 14.25 52 35017 13878 46637115
Escherichia test positive 41.57 14.25 23 35046 1949 46649044
Arthralgia 41.55 14.25 138 34931 364465 46286528
Movement disorder 41.46 14.25 57 35012 16792 46634201
Full blood count abnormal 40.95 14.25 21 35048 1526 46649467
Vomiting 40.40 14.25 189 34880 452605 46198388
Burning sensation 39.95 14.25 97 34972 44314 46606679
Vitamin B12 increased 39.78 14.25 15 35054 517 46650476
Wheelchair user 39.71 14.25 29 35040 3979 46647014
Drug interaction 39.57 14.25 57 35012 203037 46447956
Magnetic resonance imaging abnormal 39.53 14.25 25 35044 2711 46648282
Hemiparesis 39.37 14.25 61 35008 20008 46630985
Pancytopenia 39.32 14.25 8 35061 85050 46565943
Optic neuritis 39.10 14.25 36 35033 6835 46644158
Abdominal pain 38.79 14.25 71 34998 229960 46421033
Muscle spasms 38.70 14.25 189 34880 122924 46528069
Nitrite urine present 38.44 14.25 16 35053 718 46650275
Urine odour abnormal 38.41 14.25 31 35038 4931 46646062
Pleural effusion 37.93 14.25 8 35061 82944 46568049
Respiratory failure 37.90 14.25 12 35057 94804 46556189
General symptom 37.77 14.25 23 35046 2332 46648661
Systemic lupus erythematosus 37.61 14.25 3 35066 65177 46585816
Urine abnormality 37.18 14.25 32 35037 5562 46645431
Cognitive disorder 36.92 14.25 84 34985 36799 46614194
Joint swelling 34.99 14.25 44 35025 166029 46484964
Intentional overdose 34.81 14.25 4 35065 64940 46586053
Generalised tonic-clonic seizure 34.37 14.25 68 35001 27054 46623939
Urinary tract infection bacterial 34.33 14.25 27 35042 4138 46646855
B-lymphocyte count abnormal 34.32 14.25 8 35061 46 46650947
Feeling abnormal 33.76 14.25 184 34885 124876 46526117
Cardiac arrest 33.46 14.25 13 35056 90386 46560607
Prescribed underdose 33.07 14.25 43 35026 12010 46638983
Urinary tract infection pseudomonal 32.94 14.25 15 35054 838 46650155
Platelet count decreased 32.92 14.25 17 35052 100007 46550986
Tremor 32.47 14.25 172 34897 115467 46535526
Hyponatraemia 32.21 14.25 18 35051 101314 46549679
Infusion related reaction 32.14 14.25 18 35051 101190 46549803
Tongue biting 31.78 14.25 17 35052 1347 46649646
Death 31.72 14.25 137 34932 335411 46315582
Thrombocytopenia 31.71 14.25 29 35040 126552 46524441
Acute disseminated encephalomyelitis 31.65 14.25 10 35059 200 46650793
Musculoskeletal disorder 31.55 14.25 48 35021 15497 46635496
Product use issue 31.27 14.25 16 35053 94628 46556365
Fatigue 30.58 14.25 633 34436 608064 46042929
Ankle fracture 30.22 14.25 47 35022 15464 46635529
Lymphocyte percentage decreased 30.13 14.25 21 35048 2678 46648315
Cystitis 29.55 14.25 84 34985 42157 46608836
Extra dose administered 29.42 14.25 26 35043 4681 46646312
Decreased appetite 29.09 14.25 64 35005 193772 46457221
Blood immunoglobulin M decreased 29.03 14.25 13 35056 698 46650295
Treatment failure 28.92 14.25 17 35052 93070 46557923
Hypokinesia 28.91 14.25 39 35030 11283 46639710
Insurance issue 27.59 14.25 17 35052 1761 46649232
Bladder disorder 27.24 14.25 30 35039 7048 46643945
Glycosylated haemoglobin increased 27.07 14.25 37 35032 10839 46640154
Invasive ductal breast carcinoma 27.01 14.25 28 35041 6140 46644853
Immune reconstitution inflammatory syndrome 26.91 14.25 27 35042 5698 46645295
Coordination abnormal 26.88 14.25 37 35032 10912 46640081
Psoriasis 26.40 14.25 13 35056 78591 46572402
Overdose 25.97 14.25 23 35046 101956 46549037
Hypoxia 25.85 14.25 4 35065 51834 46599159
Pyrexia 25.81 14.25 155 34914 348647 46302346
Contraindicated product administered 25.70 14.25 14 35055 79933 46571060
Sinusitis 25.67 14.25 36 35033 129732 46521261
Lymphocyte percentage abnormal 25.49 14.25 5 35064 10 46650983
Cardiac failure congestive 25.47 14.25 19 35050 91731 46559262
Status epilepticus 25.36 14.25 41 35028 13938 46637055
Hyperkalaemia 25.09 14.25 4 35065 50705 46600288
Weight increased 24.92 14.25 54 35015 164419 46486574
Bacterial test positive 24.86 14.25 23 35046 4393 46646600
International normalised ratio increased 24.84 14.25 3 35066 46880 46604113
Urinary sediment present 24.73 14.25 16 35053 1804 46649189
Product use in unapproved indication 24.67 14.25 19 35050 90254 46560739
Asthma 24.10 14.25 20 35049 91522 46559471
Maternal exposure during pregnancy 23.94 14.25 25 35044 102524 46548469
Headache 23.81 14.25 497 34572 477855 46173138
Paraparesis 23.80 14.25 16 35053 1923 46649070
Tachycardia 23.58 14.25 24 35045 99598 46551395
Plasma cell myeloma 23.19 14.25 3 35066 44475 46606518
Rash 23.04 14.25 165 34904 356347 46294646
Cardiac failure 22.92 14.25 16 35053 79932 46571061
Oxygen saturation decreased 22.39 14.25 12 35057 69152 46581841
Human papilloma virus test positive 22.39 14.25 9 35060 369 46650624
Urine ketone body present 22.36 14.25 16 35053 2126 46648867
Stress 22.18 14.25 87 34982 51464 46599529
Lower respiratory tract infection 21.96 14.25 7 35062 55082 46595911
Protein urine present 21.95 14.25 23 35046 5108 46645885
Proteus test positive 21.79 14.25 7 35062 148 46650845
Electrocardiogram QT prolonged 21.41 14.25 6 35063 51319 46599674
Muscle tightness 21.17 14.25 32 35037 10273 46640720
Renal failure 21.02 14.25 33 35036 113561 46537432
Cystitis klebsiella 21.00 14.25 7 35062 167 46650826
Incontinence 20.79 14.25 31 35038 9831 46641162
Anaphylactic reaction 20.73 14.25 7 35062 53105 46597888
Urinary tract infection enterococcal 20.63 14.25 16 35053 2402 46648591
Skin laceration 20.62 14.25 44 35025 18458 46632535
Relapsing-remitting multiple sclerosis 20.54 14.25 9 35060 459 46650534
Diplopia 20.32 14.25 45 35024 19360 46631633
Red blood cell count abnormal 20.21 14.25 11 35058 902 46650091
Cardio-respiratory arrest 19.96 14.25 10 35059 59859 46591134
Multiple organ dysfunction syndrome 19.86 14.25 7 35062 51703 46599290
Hypoglycaemia 19.80 14.25 8 35061 54341 46596652
Limb discomfort 19.68 14.25 49 35020 22727 46628266
Feeling hot 19.67 14.25 68 35001 37860 46613133
Disease progression 19.41 14.25 24 35045 91276 46559717
Urinary retention 19.38 14.25 53 35016 26008 46624985
Lower limb fracture 19.35 14.25 34 35035 12364 46638629
Metabolic acidosis 19.32 14.25 3 35066 38777 46612216
Rhabdomyolysis 19.24 14.25 4 35065 41905 46609088
Stomatitis 19.14 14.25 14 35055 68283 46582710
Initial insomnia 19.12 14.25 20 35049 4432 46646561
Postictal paralysis 19.02 14.25 5 35064 50 46650943
Hip fracture 18.75 14.25 53 35016 26503 46624490
Bone pain 18.62 14.25 6 35063 46884 46604109
Atrial fibrillation 18.32 14.25 31 35038 103559 46547434
Ascites 17.85 14.25 3 35066 36581 46614412
Urinary tract infection staphylococcal 17.82 14.25 7 35062 270 46650723
Transferrin saturation decreased 17.42 14.25 8 35061 456 46650537
Pain 17.41 14.25 253 34816 476695 46174298
Blood thyroid stimulating hormone decreased 17.27 14.25 18 35051 3971 46647022
Neuropathy peripheral 17.20 14.25 26 35043 90867 46560126
Neutrophil percentage increased 17.11 14.25 15 35054 2672 46648321
Oedema peripheral 17.09 14.25 62 35007 159644 46491349
Sensory disturbance 17.06 14.25 32 35037 12235 46638758
Decreased interest 16.94 14.25 16 35053 3136 46647857
Postictal state 16.72 14.25 10 35059 981 46650012
Bronchitis 16.71 14.25 34 35035 105945 46545048
Chronic kidney disease 16.64 14.25 5 35064 40866 46610127
Therapeutic response changed 16.59 14.25 9 35060 733 46650260
Mean cell haemoglobin increased 16.58 14.25 13 35056 1983 46649010
Bladder dysfunction 16.53 14.25 9 35060 739 46650254
Migraine without aura 16.51 14.25 6 35063 186 46650807
CD4 lymphocyte percentage decreased 16.51 14.25 3 35066 3 46650990
Focal dyscognitive seizures 16.45 14.25 15 35054 2813 46648180
Urge incontinence 16.43 14.25 9 35060 748 46650245
Hepatic function abnormal 16.40 14.25 3 35066 34418 46616575
Dehydration 16.38 14.25 63 35006 159477 46491516
Infection 16.26 14.25 49 35020 133543 46517450
Injection site scar 16.17 14.25 9 35060 771 46650222
Mean cell haemoglobin decreased 16.07 14.25 15 35054 2897 46648096
Weight decreased 15.93 14.25 93 34976 210756 46440237
Dyspnoea exertional 15.88 14.25 9 35060 50280 46600713
Breast cancer 15.83 14.25 72 34997 45446 46605547
Suicide attempt 15.79 14.25 11 35058 55025 46595968
Haematocrit abnormal 15.78 14.25 9 35060 808 46650185
Depressed level of consciousness 15.77 14.25 8 35061 47561 46603432
Cough 15.62 14.25 105 34964 230144 46420849
Citrobacter infection 15.56 14.25 7 35062 380 46650613
Vitamin D increased 15.54 14.25 7 35062 381 46650612
Vitamin D decreased 15.49 14.25 24 35045 7869 46643124
Glossodynia 15.42 14.25 7 35062 44366 46606627
Urinary tract disorder 15.16 14.25 13 35056 2247 46648746
General physical health deterioration 15.16 14.25 41 35028 115728 46535265
Eye contusion 15.14 14.25 11 35058 1497 46649496
Therapeutic product effect incomplete 15.13 14.25 22 35047 78131 46572862
Coma 15.04 14.25 13 35056 58336 46592657
Specific gravity urine abnormal 14.98 14.25 3 35066 7 46650986
Hypokalaemia 14.96 14.25 27 35042 87997 46562996
Pulmonary oedema 14.95 14.25 10 35059 51095 46599898
Neutrophil count increased 14.86 14.25 33 35036 14220 46636773
Arthritis 14.74 14.25 22 35047 77294 46573699
Blood thyroid stimulating hormone increased 14.66 14.25 20 35049 5849 46645144
Glucose urine present 14.61 14.25 8 35061 664 46650329
B-lymphocyte count increased 14.56 14.25 5 35064 131 46650862
Back pain 14.54 14.25 230 34839 209809 46441184
Haematochezia 14.53 14.25 5 35064 37488 46613505
Decreased vibratory sense 14.38 14.25 6 35063 271 46650722

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 818.26 20.76 258 11019 10604 29930597
Gait disturbance 532.01 20.76 337 10940 74440 29866761
Multiple sclerosis 527.69 20.76 168 11109 7099 29934102
Laboratory test abnormal 326.77 20.76 150 11127 17292 29923909
Urinary tract infection 286.12 20.76 230 11047 73429 29867772
Balance disorder 235.22 20.76 155 11122 36338 29904863
Drug ineffective 217.88 20.76 426 10851 339961 29601240
Fall 217.08 20.76 302 10975 181570 29759631
Muscular weakness 147.95 20.76 149 11128 63496 29877705
Muscle spasticity 140.77 20.76 58 11219 5130 29936071
B-lymphocyte count decreased 102.87 20.76 26 11251 464 29940737
Mobility decreased 102.31 20.76 82 11195 25917 29915284
Therapy cessation 99.07 20.76 65 11212 15072 29926129
Insomnia 99.07 20.76 147 11130 93189 29848012
Secondary progressive multiple sclerosis 94.55 20.76 23 11254 348 29940853
Seizure 87.61 20.76 143 11134 98332 29842869
Gait inability 71.08 20.76 58 11219 18783 29922418
Flushing 68.30 20.76 69 11208 29423 29911778
Central nervous system lesion 66.93 20.76 34 11243 4872 29936329
Therapeutic response unexpected 60.12 20.76 39 11238 8864 29932337
Product substitution issue 58.22 20.76 40 11237 9995 29931206
Influenza like illness 55.83 20.76 58 11219 25547 29915654
Peroneal nerve palsy 55.17 20.76 24 11253 2425 29938776
Trigeminal neuralgia 54.10 20.76 18 11259 870 29940331
Acute kidney injury 54.01 20.76 18 11259 273824 29667377
Memory impairment 53.62 20.76 68 11209 37106 29904095
Anaemia 52.28 20.76 8 11269 207984 29733217
Progressive multifocal leukoencephalopathy 50.11 20.76 35 11242 8978 29932223
JC polyomavirus test positive 48.52 20.76 15 11262 571 29940630
Movement disorder 47.21 20.76 35 11242 9848 29931353
Hypotension 45.49 20.76 10 11267 200555 29740646
Lymphocyte count decreased 44.87 20.76 45 11232 19010 29922191
Ataxia 44.73 20.76 36 11241 11426 29929775
Inappropriate schedule of product administration 44.10 20.76 64 11213 39664 29901537
Toxicity to various agents 39.83 20.76 9 11268 177174 29764027
Paraesthesia 37.93 20.76 71 11206 54256 29886945
Drug interaction 37.78 20.76 14 11263 199554 29741647
Asthenia 37.08 20.76 173 11104 221117 29720084
Relapsing-remitting multiple sclerosis 36.41 20.76 10 11267 249 29940952
Lymphocyte percentage decreased 36.07 20.76 17 11260 2069 29939132
Full blood count abnormal 35.71 20.76 14 11263 1086 29940115
White blood cells urine positive 35.48 20.76 14 11263 1105 29940096
Gait spastic 35.32 20.76 9 11268 166 29941035
Urine analysis abnormal 34.71 20.76 16 11261 1852 29939349
Urinary incontinence 34.47 20.76 37 11240 16903 29924298
Vitamin B12 increased 33.24 20.76 9 11268 212 29940989
Renal failure 32.27 20.76 5 11272 128961 29812240
Walking aid user 32.00 20.76 14 11263 1433 29939768
Paraparesis 31.90 20.76 15 11262 1816 29939385
Dizziness 31.61 20.76 151 11126 194758 29746443
CD8 lymphocytes decreased 30.92 20.76 7 11270 76 29941125
Cognitive disorder 30.51 20.76 41 11236 23649 29917552
Neutropenia 29.95 20.76 6 11271 128534 29812667
Progressive multiple sclerosis 29.09 20.76 8 11269 200 29941001
T-lymphocyte count decreased 29.06 20.76 8 11269 201 29941000
Dyspnoea 28.81 20.76 51 11226 333244 29607957
Decreased vibratory sense 28.42 20.76 9 11268 371 29940830
Back pain 27.47 20.76 93 11184 102503 29838698
Adverse drug reaction 26.71 20.76 38 11239 23107 29918094
Hypoaesthesia 26.25 20.76 61 11216 54169 29887032
Cystitis 25.88 20.76 23 11254 8351 29932850
Thrombocytopenia 25.27 20.76 10 11267 137034 29804167
General symptom 25.02 20.76 10 11267 816 29940385
Micturition urgency 24.23 20.76 17 11260 4390 29936811
Dysstasia 23.25 20.76 24 11253 10481 29930720
Muscle spasms 23.14 20.76 65 11212 64773 29876428
Bladder disorder 22.98 20.76 14 11263 2849 29938352
Urosepsis 22.82 20.76 24 11253 10708 29930493
Musculoskeletal stiffness 22.70 20.76 45 11232 35836 29905365
Depression 22.48 20.76 80 11197 90357 29850844
Spinal cord injury cauda equina 21.97 20.76 6 11271 146 29941055
Pancytopenia 21.96 20.76 3 11274 85049 29856152
Somatosensory evoked potentials abnormal 21.82 20.76 6 11271 150 29941051
Cardiac failure 21.40 20.76 3 11274 83415 29857786
Neurogenic bladder 21.31 20.76 11 11266 1628 29939573
Product dose omission issue 21.04 20.76 79 11198 91552 29849649
Vitamin B6 deficiency 20.84 20.76 6 11271 178 29941023

Pharmacologic Action:

SourceCodeDescription
ATC N07XX07 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026902 Potassium Channel Blockers
FDA EPC N0000192795 Potassium Channel Blocker
CHEBI has role CHEBI:33289 avicides
CHEBI has role CHEBI:71031 orphan drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Multiple sclerosis indication 24700007 DOID:2377
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated potassium channel Ion channel BLOCKER CHEMBL CHEMBL
Potassium voltage-gated channel subfamily C member 1 Unclassified BLOCKER IC50 4.50 IUPHAR
Potassium voltage-gated channel subfamily C member 2 Unclassified BLOCKER IC50 4.60 IUPHAR

External reference:

IDSource
4029704 VUID
N0000180628 NUI
D04127 KEGG_DRUG
4025700 VANDF
4025705 VANDF
4029704 VANDF
C0000477 UMLSCUI
CHEBI:34385 CHEBI
4AP PDB_CHEM_ID
CHEMBL284348 ChEMBL_ID
1727 PUBCHEM_CID
DB06637 DRUGBANK_ID
D015761 MESH_DESCRIPTOR_UI
2416 IUPHAR_LIGAND_ID
7283 INN_ID
BH3B64OKL9 UNII
897018 RXNORM
170373 MMSL
26967 MMSL
NOCODE MMSL
d07546 MMSL
006829 NDDF
413355004 SNOMEDCT_US
80994002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0054-0479 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0509 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA authorized generic 27 sections
AMPYRA HUMAN PRESCRIPTION DRUG LABEL 1 10144-427 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 16729-292 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
DALFAMPRIDINE HUMAN PRESCRIPTION DRUG LABEL 1 42571-275 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine HUMAN PRESCRIPTION DRUG LABEL 1 51407-246 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 29 sections
Dalfampridine Human Prescription Drug Label 1 62756-429 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 27 sections
DALFAMPRIDINE Human Prescription Drug Label 1 65862-863 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
Dalfampridine Human Prescription Drug Label 1 67877-444 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections